New Efficiencies Lower Study Timelines While Maintaining Quality Standards
Following improvements to our Electronic Lab Notebook (ELN) system, XenoTech is experiencing increased efficiency across our portfolio of ADME/DMPK and drug-drug interaction studies. This is also resulting in shorter lead times for clients, allowing them to start their studies more quickly. The benefits are only initial and are expected to increase over time.
Studies that have already seen timeline improvements include:
- Metabolic stability studies to measure intrinsic clearance and determine the extent to which a drug will be metabolized.
- Metabolite identification/profiling/characterization studies to identify the number, putative structure, and proposed biotransformation of metabolites produced as a result of interaction with drug-metabolizing enzymes at various sites of metabolism.
- Reaction phenotyping studies to identify enzymes responsible for the elimination of a compound and understand the potential for drug-drug interactions.
- Enzyme inhibition studies to predict a compound’s inhibitory effect on drug-metabolizing enzymes, such as cytochrome P450s (CYPs) and UDP glucuronyltransferases (UGTs).
- Enzyme induction studies to predict a compound’s potential to increase clearance of a concomitant victim drug by up-regulating (inducing) enzymes that metabolize it.
- Drug transport studies to investigate a compound’s potential to operate as a substrate or inhibitor of known uptake (SLC) and efflux (ABC) transporters.
- Microsomal and plasma protein binding studies to determine free drug concentration (fraction unbound, fu) in plasma or in the presence of microsomes for clinical dosage considerations, PK-related calculations, modeling, and definitive in vitro study design.
- Red blood cell partitioning studies to determine your drug’s blood to plasma ratio to evaluate its tendency to bind to or become sequestered in red blood cells.
- Lysosomal trapping studies to predict propensity for membrane-bound organelles within hepatocytes to sequester lipophilic amine drugs, potentially limiting clearance and reducing therapeutic effect.
To take advantage of these new improvements, contact our experts to discuss which studies are currently appropriate for your compound and reserve your spot in the queue today.